Itepekimab Biosimilar – Anti-IL33 mAb – Research Grade from ProteoGenix; catalogue PX-TA1852; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Title: Understanding the Structure and Function of Itepekimab Biosimilar – Anti-IL33 mAb
Itepekimab Biosimilar, also known as Anti-IL33 mAb, is a promising therapeutic antibody that has shown potential in treating various inflammatory and autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of this novel biosimilar.
Itepekimab Biosimilar is a monoclonal antibody (mAb) that is designed to target the cytokine interleukin-33 (IL-33). It is a humanized IgG1 antibody, meaning that it is derived from human sources and has been modified to reduce potential immunogenicity. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, connected by disulfide bonds.
IL-33 is a pro-inflammatory cytokine that plays a crucial role in the development and progression of various inflammatory and autoimmune diseases. It is known to activate immune cells such as mast cells, eosinophils, and Th2 cells, leading to the release of other pro-inflammatory cytokines. Itepekimab Biosimilar works by binding to IL-33 and preventing its interaction with its receptor, thereby inhibiting its pro-inflammatory effects.
Due to its mechanism of action, Itepekimab Biosimilar has the potential to treat a wide range of inflammatory and autoimmune diseases. Some of the diseases that have been identified as potential targets for this biosimilar include asthma, atopic dermatitis, rheumatoid arthritis, and inflammatory bowel disease. In preclinical studies, Itepekimab Biosimilar has shown promising results in reducing disease severity and improving symptoms in these conditions.
There are currently other anti-IL33 mAbs in development, but Itepekimab Biosimilar stands out due to its unique structure and potential advantages. One of the main advantages of this biosimilar is its humanized structure, which reduces the risk of immunogenicity and increases its potential for clinical success. Additionally, Itepekimab Biosimilar has shown high affinity and specificity for IL-33, making it a potent inhibitor of IL-33 activity.
Apart from its potential therapeutic applications, Itepekimab Biosimilar is also available in a research grade form. This allows researchers to study the structure and function of this antibody in more detail and explore its potential in various disease models. The research grade version of Itepekimab Biosimilar is produced under strict quality control measures to ensure its purity and activity.
In conclusion, Itepekimab Biosimilar is a promising therapeutic antibody that has the potential to treat various inflammatory and autoimmune diseases. Its unique structure and mechanism of action make it a potent inhibitor of IL-33 activity. With ongoing research and development, Itepekimab Biosimilar has the potential to provide a safe and effective treatment option for patients with these debilitating conditions.
ProteoGenix catalogue number PX-TA1852. For research use only.
Target: Itepekimab Biosimilar – Anti-IL33 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Itepekimab Biosimilar – Anti-IL33 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
